Multiple primary non-breast tumors in breast cancer survivors

Abstract

Older age represents the major risk of developing a second primary non-breast cancer, excluding ovarian cancer. Clinical surveillance is required to prevent ovarian and thyroid cancers, respectively, in patients with positive family history, triple negative, G3 breast cancer and during hormonal therapy treatment in postmenopausal status.

Incidence of second primary malignancy after breast cancer and related risk factors—Is breast‐conserving surgery safe? A nested case–control study

“…In terms of the risks of SPM at specific sites, our findings were comparable with previous observations for SPMs in the digestive system, respiratory system, genital system, endocrine system, hematopoietic system and contralateral breast . Based on our analysis of the site‐specific adjusted SIRs, we found an inverse association of age with SPM risk, which was in agreement with several studies but only inconsistent with a retrospective study from Italy . In that Italian study, an increased risk of all the second non‐BCs, except for ovarian tumor, was revealed among older‐aged patients at onset of the diagnosis of primary BC .…”

“…[29][30][31][32] Based on our analysis of the site-specific adjusted SIRs, we found an inverse association of age with SPM risk, which was in agreement with several studies 29,[33][34][35][36] but only inconsistent with a retrospective study from Italy. 37 In that Italian study, an increased risk of all the second non-BCs, except for ovarian tumor, was revealed among older-aged patients at onset of the diagnosis of primary BC. 37 Although the use of intensive screening during follow-up increased the detection rate of novel second primary cancers, indeed, they seemed to have lost sight of the fact that general elders often had a high risk of cancer incidence and limited life expectancy to develop the second cancers.…”

“…37 In that Italian study, an increased risk of all the second non-BCs, except for ovarian tumor, was revealed among older-aged patients at onset of the diagnosis of primary BC. 37 Although the use of intensive screening during follow-up increased the detection rate of novel second primary cancers, indeed, they seemed to have lost sight of the fact that general elders often had a high risk of cancer incidence and limited life expectancy to develop the second cancers. In our view, the adjusted SIR can truly reflect the additional risk attributing to primary BC and our study shows a convincing evidence that younger-aged BC patients constitute the high-risk group of developing a second nonbreast cancer after BC diagnosis compared to the general population.…”

The Melanoma and Breast Cancer Association: An Overview of their ‘Second Primary Cancers’ and the Epidemiological, Genetic and Biological correlations

“…A meta-analysis in 2015 of thirteen studies combining 1,346,671 primary female breast cancer survivors found a 17% increase in the risk of developing a new primary non-breast cancer in comparison to those that had never received a breast carcinoma diagnosis (22). Sites of second primary cancers consistently reported include the soft tissue (sarcoma) (SIR range 2.25-13) (11,(23)(24)(25), ovary (SIR range 1.6-5.7) (11,12,18,21,(23)(24)(25)(26)(27)(28)(29)(30)(31), thyroid gland (SIR range 1.54-1.62) (12,21,24,32), endometrium (SIR range 1.3-1.52) (11,12,21,23,24,27,29,30,32,33), leukaemia (SIR range 1.2-3.1) (11,12,23,29) and lung (SIR range 1.2-1.24) (18,19,21,25,29,32,34). Studies have postulated the likely causes for these associations.…”

Multiparametric ultrasound diagnosis of metastatic and lymphoproliferative changes in lymph nodes in primary-multiple malignant tumors, including breast cancer and lymphoma

“…Кроме того, увеличение числа случаев ПМЗО отмечено у пациентов, у которых лечение первичной опухоли включало лучевую терапию (ЛТ) и химиотерапию (ХТ) [3][4][5][6]. Так, в исследование Ж. Корсо (G. Corso) с соавторами [7] было включено 21 527 женщин, перенесших комбинированное лечение рака молочной железы, из которых у 4,1 % впоследствии были выявлены метахронные злокачественные опухоли других локализаций.…”